Literature DB >> 20644257

MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice.

Denghong Zhang1, Riccardo Contu, Michael V G Latronico, Jianlin Zhang, Jian Ling Zhang, Roberto Rizzi, Daniele Catalucci, Shigeki Miyamoto, Katherine Huang, Marcello Ceci, Yusu Gu, Nancy D Dalton, Kirk L Peterson, Kun-Liang Guan, Joan Heller Brown, Ju Chen, Nahum Sonenberg, Gianluigi Condorelli.   

Abstract

Mechanistic target of rapamycin (MTOR) plays a critical role in the regulation of cell growth and in the response to energy state changes. Drugs inhibiting MTOR are increasingly used in antineoplastic therapies. Myocardial MTOR activity changes during hypertrophy and heart failure (HF). However, whether MTOR exerts a positive or a negative effect on myocardial function remains to be fully elucidated. Here, we show that ablation of Mtor in the adult mouse myocardium results in a fatal, dilated cardiomyopathy that is characterized by apoptosis, autophagy, altered mitochondrial structure, and accumulation of eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1). 4E-BP1 is an MTOR-containing multiprotein complex-1 (MTORC1) substrate that inhibits translation initiation. When subjected to pressure overload, Mtor-ablated mice demonstrated an impaired hypertrophic response and accelerated HF progression. When the gene encoding 4E-BP1 was ablated together with Mtor, marked improvements were observed in apoptosis, heart function, and survival. Our results demonstrate a role for the MTORC1 signaling network in the myocardial response to stress. In particular, they highlight the role of 4E-BP1 in regulating cardiomyocyte viability and in HF. Because the effects of reduced MTOR activity were mediated through increased 4E-BP1 inhibitory activity, blunting this mechanism may represent a novel therapeutic strategy for improving cardiac function in clinical HF.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20644257      PMCID: PMC2912201          DOI: 10.1172/JCI43008

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  59 in total

1.  Akt1 is required for physiological cardiac growth.

Authors:  Brian DeBosch; Iya Treskov; Traian S Lupu; Carla Weinheimer; Attila Kovacs; Michael Courtois; Anthony J Muslin
Journal:  Circulation       Date:  2006-04-24       Impact factor: 29.690

Review 2.  TOR signaling in growth and metabolism.

Authors:  Stephan Wullschleger; Robbie Loewith; Michael N Hall
Journal:  Cell       Date:  2006-02-10       Impact factor: 41.582

3.  Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.

Authors:  D D Sarbassov; David A Guertin; Siraj M Ali; David M Sabatini
Journal:  Science       Date:  2005-02-18       Impact factor: 47.728

4.  Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis.

Authors:  Xiao-Ming Gao; Geoffrey Wong; Binghui Wang; Helen Kiriazis; Xiao-Lei Moore; Yi-Dan Su; Anthony Dart; Xiao-Jun Du
Journal:  J Hypertens       Date:  2006-08       Impact factor: 4.844

5.  Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1.

Authors:  David A Guertin; Deanna M Stevens; Carson C Thoreen; Aurora A Burds; Nada Y Kalaany; Jason Moffat; Michael Brown; Kevin J Fitzgerald; David M Sabatini
Journal:  Dev Cell       Date:  2006-12       Impact factor: 12.270

6.  Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism.

Authors:  A C Gingras; S P Gygi; B Raught; R D Polakiewicz; R T Abraham; M F Hoekstra; R Aebersold; N Sonenberg
Journal:  Genes Dev       Date:  1999-06-01       Impact factor: 11.361

7.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB.

Authors:  Dos D Sarbassov; Siraj M Ali; Shomit Sengupta; Joon-Ho Sheen; Peggy P Hsu; Alex F Bagley; Andrew L Markhard; David M Sabatini
Journal:  Mol Cell       Date:  2006-04-06       Impact factor: 17.970

8.  Selective requirement of myosin light chain 2v in embryonic heart function.

Authors:  J Chen; S W Kubalak; S Minamisawa; R L Price; K D Becker; R Hickey; J Ross; K R Chien
Journal:  J Biol Chem       Date:  1998-01-09       Impact factor: 5.157

9.  High-efficiency CAG-FLPe deleter mice in C57BL/6J background.

Authors:  Hiroaki Kanki; Hitomi Suzuki; Shigeyoshi Itohara
Journal:  Exp Anim       Date:  2006-04

10.  Adenoviral RB2/p130 gene transfer inhibits smooth muscle cell proliferation and prevents restenosis after angioplasty.

Authors:  P P Claudio; L Fratta; F Farina; C M Howard; G Stassi; S Numata; C Pacilio; A Davis; M Lavitrano; M Volpe; J M Wilson; B Trimarco; A Giordano; G Condorelli
Journal:  Circ Res       Date:  1999-11-26       Impact factor: 17.367

View more
  173 in total

1.  MicroRNA-221 inhibits autophagy and promotes heart failure by modulating the p27/CDK2/mTOR axis.

Authors:  M Su; J Wang; C Wang; X Wang; W Dong; W Qiu; Y Wang; X Zhao; Y Zou; L Song; L Zhang; R Hui
Journal:  Cell Death Differ       Date:  2014-11-14       Impact factor: 15.828

2.  Target of rapamcyin (TOR)-based therapeutics for cardiomyopathy: insights from zebrafish genetics.

Authors:  Yonghe Ding; Xiaojing Sun; Margaret Redfield; Sudhir Kushwaha; Xiaolei Xu
Journal:  Cell Cycle       Date:  2012-02-01       Impact factor: 4.534

3.  Rheb is a critical regulator of autophagy during myocardial ischemia: pathophysiological implications in obesity and metabolic syndrome.

Authors:  Sebastiano Sciarretta; Peiyong Zhai; Dan Shao; Yasuhiro Maejima; Jeffrey Robbins; Massimo Volpe; Gianluigi Condorelli; Junichi Sadoshima
Journal:  Circulation       Date:  2012-01-31       Impact factor: 29.690

4.  Arrest of myelination and reduced axon growth when Schwann cells lack mTOR.

Authors:  Diane L Sherman; Michiel Krols; Lai-Man N Wu; Matthew Grove; Klaus-Armin Nave; Yann-Gaël Gangloff; Peter J Brophy
Journal:  J Neurosci       Date:  2012-02-01       Impact factor: 6.167

5.  CYLD exaggerates pressure overload-induced cardiomyopathy via suppressing autolysosome efflux in cardiomyocytes.

Authors:  Lei Qi; Huimei Zang; Weiwei Wu; Prakash Nagarkatti; Mitzi Nagarkatti; Qinghang Liu; Jeffrey Robbins; Xuejun Wang; Taixing Cui
Journal:  J Mol Cell Cardiol       Date:  2020-06-14       Impact factor: 5.000

6.  Haploinsufficiency of target of rapamycin attenuates cardiomyopathies in adult zebrafish.

Authors:  Yonghe Ding; Xiaojing Sun; Wei Huang; Tiffany Hoage; Margaret Redfield; Sudhir Kushwaha; Sridhar Sivasubbu; Xueying Lin; Stephen Ekker; Xiaolei Xu
Journal:  Circ Res       Date:  2011-07-14       Impact factor: 17.367

Review 7.  The mTOR Signaling Pathway in Myocardial Dysfunction in Type 2 Diabetes Mellitus.

Authors:  Tomohiro Suhara; Yuichi Baba; Briana K Shimada; Jason K Higa; Takashi Matsui
Journal:  Curr Diab Rep       Date:  2017-06       Impact factor: 4.810

Review 8.  Molecular basis of physiological heart growth: fundamental concepts and new players.

Authors:  Marjorie Maillet; Jop H van Berlo; Jeffery D Molkentin
Journal:  Nat Rev Mol Cell Biol       Date:  2013-01       Impact factor: 94.444

Review 9.  Targeting Autophagy in Aging and Aging-Related Cardiovascular Diseases.

Authors:  Jun Ren; Yingmei Zhang
Journal:  Trends Pharmacol Sci       Date:  2018-10-26       Impact factor: 14.819

Review 10.  Target of rapamycin (TOR)-based therapy for cardiomyopathy: evidence from zebrafish and human studies.

Authors:  Sudhir Kushwaha; Xiaolei Xu
Journal:  Trends Cardiovasc Med       Date:  2012-07-28       Impact factor: 6.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.